Compare NGEN & APYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGEN | APYX |
|---|---|---|
| Founded | 2017 | 1982 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.5M | 196.4M |
| IPO Year | 2018 | 1995 |
| Metric | NGEN | APYX |
|---|---|---|
| Price | $1.86 | $3.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $18.00 | $6.50 |
| AVG Volume (30 Days) | ★ 375.0K | 110.1K |
| Earning Date | 04-02-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $11.93 |
| Revenue Next Year | N/A | $11.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.58 | $1.70 |
| 52 Week High | $5.93 | $5.08 |
| Indicator | NGEN | APYX |
|---|---|---|
| Relative Strength Index (RSI) | 57.39 | 33.81 |
| Support Level | $1.59 | $2.99 |
| Resistance Level | $2.22 | $4.31 |
| Average True Range (ATR) | 0.09 | 0.31 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 95.35 | 13.77 |
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.